Lv1
90 积分 2023-12-20 加入
Trends in innovative drug development in China
16小时前
已完结
Approvals by the China NMPA in 2024
16小时前
已完结
Newly approved cancer drugs in China — innovation and clinical benefit
16小时前
已完结
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
2天前
已完结
Blocking the neonatal Fc receptor as a novel approach to prevent cardiac neonatal lupus: a proof-of-concept study
1个月前
已关闭
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
1个月前
已完结
Brigatinib in NF2 -Related Schwannomatosis with Progressive Tumors
1个月前
已完结
Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report
1个月前
已完结
Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer
1个月前
已完结
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
1个月前
已完结
皖公网安备34019202002308
